News Sentiment

SPRO sentiment intelligence

Spero Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 59 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.10 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

78/100 classification confidence.

Company focus 51

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend inactive

-4.5% over one week, -26.3% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

Innovent licenses IBI355 rights to Spero for up to $1.1bn

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 78/100 classification
One-week reaction -4.5% Price reacting lower
Trend fit Trend inactive -26.3% over four weeks
Fair value 25.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 38
Negative 6

Relevance

Why the article matched

Direct first
Direct company coverage 51
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 12
Market source 6
TradingView 5
simplywall.st 5
Seeking Alpha 4
GuruFocus 4
GlobeNewswire 3
Investing.com UK 2

Event Lens

What the news is about

Classified themes
Market update 29
Earnings 13
Deals and strategy 8
Regulatory and legal 6
Balance sheet 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 59
Reuters Direct company coverage

Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion

Spero Therapeutics has licensed the rights to Innovent Biologics' experimental autoimmune disease treatment, IBI355, outside of Greater China in a deal potentially worth up to $1.1 billion. This agreement provides Spero with its first immunology asset, expanding beyond its infect

Tone
Positive 73/100
Event
Deals and strategy
Published
14 Jul 2026 14:10
Source
Reuters
GuruFocus Direct company coverage

Spero Therapeutics (SPRO) Secures $105M Financing and $1.1B Licensing Agreement

Spero Therapeutics (SPRO) announced a significant financing arrangement of $105 million with Healthcare Royalty and a licensing deal worth up to $1.1 billion with Innovent Biologics. These agreements aim to advance Spero's clinical programs, including the development of an antibo

Tone
Positive 72/100
Event
Deals and strategy
Published
14 Jul 2026 13:10
Source
GuruFocus
citybiz Direct company coverage

Spero Therapeutics Secures $105 Million Royalty Financing to Advance Immunology Pipeline

Spero Therapeutics has secured $105 million in non-dilutive royalty financing from Healthcare Royalty (HCRx) to fund the clinical development of its lead immunology drug candidate, SP001. This financing, backed by future payments from its antibiotic Utebzi, enables Spero to exten

Tone
Positive 74/100
Event
Market update
Published
14 Jul 2026 12:10
Source
citybiz
Stock Titan Direct company coverage

Spero Therapeutics (Nasdaq: SPRO) inks SP001 deal and $105M royalty financing

Spero Therapeutics has announced two significant financial and strategic moves: an exclusive worldwide licensing agreement (excluding Greater China) with Innovent Biologics for SP001, a third-generation Fc-silent anti-CD40L monoclonal antibody for which Spero paid a $35 million u

Tone
Positive 67/100
Event
Deals and strategy
Published
14 Jul 2026 10:30
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Spero Therapeutics shares fall after $105M KKR deal By Investing.com

Spero Therapeutics shares dropped about 12% in pre-market trading after announcing a $105 million licensing agreement with affiliates of Healthcare Royalty, a KKR business. Under the deal, HCRx will receive a portion of future milestone and royalty payments from Utebzi sales, wit

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 Jul 2026 10:24
Source
Investing.com Nigeria
Investing.com Direct company coverage

Spero Therapeutics shares fall after $105M KKR deal

Spero Therapeutics (SPRO) shares dropped by approximately 12% following the announcement of a $105 million licensing agreement with KKR's Healthcare Royalty business. Under the deal, HCRx will receive milestone and royalty payments from sales of Spero's drug Utebzi in exchange fo

Tone
Negative 29/100
Event
Deals and strategy
Published
14 Jul 2026 10:10
Source
Investing.com
Stock Titan Direct company coverage

Spero's $105M deal will support Phase 2 immunology drug SP001

Spero Therapeutics has secured a $105 million non-recourse, non-dilutive royalty financing from Healthcare Royalty (HCRx) to fund the Phase 2 development of its lead immunology drug candidate, SP001. This financing, backed by a portion of future milestones and royalties from Uteb

Tone
Neutral 50/100
Event
Deals and strategy
Published
14 Jul 2026 10:01
Source
Stock Titan
GlobeNewswire Direct company coverage

Spero Therapeutics and Innovent Biologics Announce Exclusive License for SP001 (IBI355), a Phase 2-Ready Third-Generation Anti-CD40L Antibody

Spero Therapeutics and Innovent Biologics have announced an exclusive licensing agreement for SP001 (IBI355), a third-generation anti-CD40L antibody. Spero receives global rights excluding Greater China and plans to initiate a Phase 2 trial for IgG4-related disease in Q2 2027. In

Tone
Positive 93/100
Event
Market update
Published
14 Jul 2026 09:59
Source
GlobeNewswire
The Business Journals Direct company coverage

Cambridge biotech strikes $1.1B deal with Chinese partner, shifts to immunology

Cambridge-based Spero Therapeutics has signed a $1.1 billion drug deal with Chinese partner Innovent Biologics. This agreement will enable Spero to shift its strategic focus towards immunology. The company is leveraging proceeds from a recent drug approval to fund this new direct

Tone
Positive 72/100
Event
Deals and strategy
Published
14 Jul 2026 09:59
Source
The Business Journals
TradingView Direct company coverage

Enterprise value to EBIT forward of Spero Therapeutics, Inc. – MUN:2HA

This article provides financial data for Spero Therapeutics, Inc. (MUN:2HA), specifically focusing on its enterprise value to EBIT forward. It indicates that the market was closed with no trades at the time of publication. The content is presented within the TradingView platform,

Tone
Neutral 50/100
Event
Market update
Published
12 Jul 2026 20:10
Source
TradingView
AD HOC NEWS Direct company coverage

Spero Therapeutics outlines its antibiotic pipeline as investors track regulatory progress

Spero Therapeutics is a clinical-stage biopharmaceutical company focusing on novel antibiotic candidates for multidrug-resistant bacterial infections. The company's strategy involves progressing assets through clinical trials, considering potential collaborations, and navigating

Tone
Positive 65/100
Event
Regulatory and legal
Published
07 Jul 2026 17:42
Source
AD HOC NEWS
TradingView Direct company coverage

Spero Therapeutics, Inc. Actuals & Estimates (NASDAQ:SPRO)

This article provides an overview of Spero Therapeutics, Inc. (SPRO) stock, including its current price, historical performance, analyst forecasts, and key financial metrics. It highlights recent stock changes, market capitalization, upcoming earnings, and past financial results,

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 16:10
Source
TradingView
TradingView Direct company coverage

Spero Therapeutics, Inc. Actuals & Estimates (BOATS:SPRO)

This article provides financial actuals and estimates for Spero Therapeutics, Inc. (SPRO), including analyst forecasts, historical price data, earnings reports, and other key financial metrics. It highlights that analysts expect a maximum and minimum price of $4.00, and the compa

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:40
Source
TradingView
Stock Titan Direct company coverage

Spero Therapeutics (NASDAQ: SPRO) doubles share authorization and adopts 2026 stock plan

Spero Therapeutics' stockholders approved a new 2026 Stock Incentive Plan covering up to 12,895,866 shares and doubled the authorized common stock from 120,000,000 to 240,000,000 shares. These actions provide the company with greater flexibility for future equity awards and poten

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 05:40
Source
Stock Titan
Stock Titan Direct company coverage

Spero Therapeutics (SPRO) grants director RSUs and 20,000 stock options

Spero Therapeutics director Frank E. Thomas received equity awards comprising 10,000 restricted stock units (RSUs) and options to purchase 20,000 shares of common stock at an exercise price of $2.15 per share. Both the RSUs and options are set to vest on June 23, 2027, contingent

Tone
Neutral 50/100
Event
Market update
Published
26 Jun 2026 04:09
Source
Stock Titan